138 related articles for article (PubMed ID: 1423291)
1. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)-benzenesulfonyl))indolizine.
Jaffrézou JP; Levade T; Chatelain P; Laurent G
Cancer Res; 1992 Dec; 52(23):6440-6. PubMed ID: 1423291
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
[TBL] [Abstract][Full Text] [Related]
3. Acidic sphingomyelinase-generated ceramide is needed but not sufficient for TNF-induced apoptosis and nuclear factor-kappa B activation.
Higuchi M; Singh S; Jaffrezou JP; Aggarwal BB
J Immunol; 1996 Jul; 157(1):297-304. PubMed ID: 8683130
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein.
Jaffrézou JP; Herbert JM; Levade T; Gau MN; Chatelain P; Laurent G
J Biol Chem; 1991 Oct; 266(29):19858-64. PubMed ID: 1918089
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
Ling YH; Priebe W; Perez-Soler R
Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
[TBL] [Abstract][Full Text] [Related]
10. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.
Gervasoni JE; Fields SZ; Krishna S; Baker MA; Rosado M; Thuraisamy K; Hindenburg AA; Taub RN
Cancer Res; 1991 Sep; 51(18):4955-63. PubMed ID: 1680024
[TBL] [Abstract][Full Text] [Related]
11. Exploring multidrug resistance using rhodamine 123.
Kessel D
Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
[TBL] [Abstract][Full Text] [Related]
12. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
13. Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells.
Ramu A; Glaubiger D; Weintraub H
Cancer Treat Rep; 1984 Apr; 68(4):637-41. PubMed ID: 6713419
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
15. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.
De Jong G; Gelmon K; Bally M; Goldie J; Mayer L
Anticancer Res; 1995; 15(3):911-6. PubMed ID: 7645981
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance.
Jaffrézou JP; Chen KG; Durán GE; Muller C; Bordier C; Laurent G; Sikic BI; Levade T
Biochim Biophys Acta; 1995 Apr; 1266(1):1-8. PubMed ID: 7718613
[TBL] [Abstract][Full Text] [Related]
17. Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells.
Ganapathi R; Reiter W; Krishan A
J Natl Cancer Inst; 1982 Jun; 68(6):1027-32. PubMed ID: 6953267
[TBL] [Abstract][Full Text] [Related]
18. Modulation of doxorubicin-induced DNA lesions by verapamil, DMDP and dipyridamole in resistant P388 cell lines.
Yin MB; Bankusli I; Frank C; Rustum YM
Anticancer Res; 1990; 10(2A):327-32. PubMed ID: 2346306
[TBL] [Abstract][Full Text] [Related]
19. Overcoming of vinblastine resistance by isoquinolinesulfonamide compounds in adriamycin-resistant leukemia cells.
Wakusawa S; Nakamura S; Tajima K; Miyamoto K; Hagiwara M; Hidaka H
Mol Pharmacol; 1992 Jun; 41(6):1034-8. PubMed ID: 1614407
[TBL] [Abstract][Full Text] [Related]
20. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
